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Abstract 
Multi-Drug Resistant (MDR) uropathogenic bacteria have increased in number in recent years and the development 
of new treatment options for the corresponding infections has become a major challenge in the field of medicine. 
In this respect, recent studies have proposed bacteriophage (phage) therapy as a potential alternative against MDR 
Urinary Tract Infections (UTI) because the resistance mechanism of phages differs from that of antibiotics and few 
side effects have been reported for them. Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis are the most 
common uropathogenic bacteria against which phage therapy has been used. Phages, in addition to lysing bacterial 
pathogens, can prevent the formation of biofilms. Besides, by inducing or producing polysaccharide depolymerase, 
phages can easily penetrate into deeper layers of the biofilm and degrade it. Notably, phage therapy has shown good 
results in inhibiting multiple-species biofilm and this may be an efficient weapon against catheter-associated UTI. 
However, the narrow range of hosts limits the use of phage therapy. Therefore, the use of phage cocktail and com-
bination therapy can form a highly attractive strategy. However, despite the positive use of these treatments, various 
studies have reported phage-resistant strains, indicating that phage–host interactions are more complicated and 
need further research. Furthermore, these investigations are limited and further clinical trials are required to make this 
treatment widely available for human use. This review highlights phage therapy in the context of treating UTIs and 
the specific considerations for this application.
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Introduction
Urinary Tract Infections (UTIs) constitute one of the 
most important concerns among medical experts and 
patients that are linked to almost 40% of the cases of 
nosocomial infections in acute care hospitals [1, 2]. 
Notably, these infections are reported as one of the 
most common bacterial infections that affecting about 
150 million people every year worldwide. UTI is one of 
the most common reason of morbidity and mortality in 
the elderly, accounting for 15.5 and 6.2% of hospitaliza-
tion and deaths of people aged 65 years or older, respec-
tively [3–5]. Women are more susceptible to UTIs than 
men due to behavioral factors, their anatomy, and prac-
tice such as use of diaphragm and spermicides [6]. UTIs 
may affect women at any age, especially women with fre-
quent sexual activities and women of childbearing age as 
well as old men and infant boys [2]. UTIs are classified as 
either lower (confined to the bladder) or upper (pyelone-
phritis) and they can be clinically divided into two forms: 
uncomplicated and complicated. Uncomplicated form 
represents the conditions when patients exhibit a healthy 
status previous to the infection without non-catheter-
ized, non-pregnant, and no structural abnormalities. On 
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the other hand, UTI is reported as complicated when 
patients are immunocompromised or experience risk 
factors such as pregnancy and urinary retention [1, 7]. 
Escherichia coli is the most common (80%) cause of the 
uncomplicated UTI and catheter-associated infections 
[8]. Other common bacteria in UTIs include Proteus 
species, Klebsiella pneumoniae, Staphylococcus aureus, 
Staphylococcus saprophyticus, and Enterococci and Enter-
obacter [2, 9]. Pseudomonas aeruginosa and Acineto-
bacter baumannii are rarely isolated from UTIs, but the 
epidemic potential of Multi-Drug Resistant (MDR) path-
ogens and high ability to cause septicemia makes these 
bacteria quite important [10]. Prophylaxis of UTIs or 
extensive and unlimited use of routine antibiotics leads to 
the emergence of MDR bacteria. Therefore, treating UTIs 
due to antibiotic resistance is becoming more difficult 
every day [5].
One of the main features of uropathogenic bacteria 
that makes them more resistant to the host immune sys-
tem and chemical antibiotics is their capacity to form 
single- or mixed-species biofilm. This structure settles 
on both abiotic and biological surfaces such as indwell-
ing urinary catheters and is characterized by low sus-
ceptibility to antibiotics and hard to remove even if the 
catheter is detached [1, 11]. Thus, the high prevalence of 
MDR bacteria has severely restricted the use of antibiot-
ics in recent years. Furthermore, a long course of antibi-
otic therapy often causes toxicity in the patients, arising 
antibiotic resistance and affected natural microbiota. So, 
interest in other treatments like phage therapy is increas-
ing. In this context, given the phages are self-replicating, 
they cannot infect eukaryotic cells and their mecha-
nisms of resistance are different from those of antibiot-
ics [12, 13]. Various studies suggests phage therapy has 
the potential to be used as either an alternative or a sup-
plement to antibiotic treatments [14, 15]. Bacteriophage 
depolymerase plays an important role in the degrada-
tion of biofilm Extracellular Polymeric Substances (EPS) 
substrate, promoting phage penetration into the biofilm 
and leading to bacterial cell lysis. Indeed, this enzyme is 
expressed on the surface of phage capsids or produced by 
host cells during phage replication and it helps phages to 
adsorb, attack, and decompose bacterial host [16]. Fur-
thermore, phages at the end of the lytic cycle produce 
endolysins. Endolysins are phage enzymes that cleave 
peptidoglycans, i.e., the main component of the bacterial 
cell wall, and they are antibacterial agents owing to their 
special mode of action and highly particular activities 
against bacteria [17]. Noteworthy, phage therapy can be 
divided into two categories: monophage and polyphage 
therapy. Two or more phages mix and they cover vari-
ous bacterial hosts in a single product as a phage cocktail 
which is typically more effective in interfering in bacterial 
infections [18, 19].
Furthermore, recent studies have reported that despite 
the presence of the different factors such as biofilms and 
other antibiotic resistance factors in UTIs, phages along 
with other antimicrobial strategies may be effective in 
preventing and treating these infections by increasing 
the synergistic effect [20, 21]. In this respect, the present 
review paper is an attempt at investigating more compre-
hensively the effectiveness of phage therapy in treating 
UTIs caused by MDR-uropathogenic bacteria.
Escherichia coli
Escherichia coli is one of the most common human path-
ogens and induces infection in different organs of the 
body including enteritis, septicemia, neonatal meningi-
tis, and UTI [22, 23]. The most frequent extra-intestinal 
E. coli infection is UTI and by far, the most common 
pathogen that induces UTI is Uropathogenic E. coli 
(UPEC) [24]. Moreover, the growing prevalence of MDR 
UPEC strains has complicated UTIs treatment and led 
to rise of costs and extended hospital stays [25]. Nowa-
days, phage therapy is considered a potential choice for 
treating the resistance of UPEC [13]. In this context, 
VB_ecoS-Golestan is reported as an alternative treat-
ment for inhibiting UPEC. Among investigated isolates, 
78.8% were MDR, of which 56% exhibited sensitivity 
to the lytic activity of this phage. This phage is charac-
terized by broad host range specificity in MDR isolates; 
besides, none of the lysogenic mediated genes was found 
in this phage genome. Therefore, the authors suggested 
that phage therapy could be a promising approach to 
the treatment of MDR E. coli. However, high specificity 
towards E. coli may be a restricting factor in applying the 
phage to treatment of multiple-species UTI [26].
Involvement of biofilms in most chronic infections is 
justified by their resistance to both antibiotics and host 
defenses. The need for effective treatments with an ability 
to penetrate the biofilm structure and destroy it can bring 
phages into attention as an antimicrobial agent to control 
and prevent biofilm formation [11]. Gu et  al. character-
ized vB_EcoP-EG1(T7-like Podoviridae family) by large 
burst size, no toxic protein, very short lytic cycle, and 
broader host range on UPEC strains. This phage brings 
about promising outcome as it can infect 10 out 21 MDR 
UPEC. In addition, this phage successfully lyses the MDR 
UPEC and reduces the biofilm biomass in sensitive and 
MDR isolates. Furthermore, vB_EcoP-EG1 shows quite a 
strong lytic ability in both planktonic and biofilm forms 
of UPEC strains. In medical settings, the biofilm induces 
destructive damage during acute and chronic infections 
such as Catheter-Associated UTI (CAUTI) by UPEC, 
and the phage may have a potential to treat patients with 
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biofilm-related UTI [27]. In another investigation, the 
authors reported three phages with activity against UPEC 
biofilm. All phages caused a reduction in biofilm biomass 
compared to the untreated group at both low and higher 
concentrations after 8 h of incubation. These results dem-
onstrate that phages act in a nondose-dependent manner, 
working to their advantage when applied to in vivo con-
dition in order to remove the biofilm. On the other hand, 
there was evidence that biofilm start to re-stablish itself 
after 24  h. This phenomenon could be linked to resist-
ance development against the phages in bacteria [28].
Therefore, phages have a limited host range and the 
activation of resistance to phage in the biofilm commu-
nity is one of the significant obstacles to successful phage 
therapy. These challenges can be overcome using phage 
cocktails and combination therapy of phage and antibiot-
ics. It has already been shown that combination therapy 
not only reduces the number of bacteria but also relates 
to the management of phage-resistant bacteria levels 
[29]. Thus, some researches have investigated the effec-
tiveness of combination therapy of phage and antibiot-
ics in UPEC inhibition. In this respect, Moradpour et al. 
probed the synergic effect of phage and ampicillin against 
drug-resistant E. coli O157-associated UTI. The E. coli 
strain used in this study was resistant to ampicillin and 
had intermediate susceptibility to amoxicillin-clavulanic 
acid. Application of the phage resulted in keeping zones 
remarkably clear of ampicillin and amoxicillin-clavulanic 
acid in disk diffusion, reduced the overall growth of bac-
teria, and indicated the sensitivity of resistance pheno-
type in the inhibition zones. Further, the modified broth 
microdilution assay confirmed the phage-antibiotic syn-
ergy [30]. This synergistic effect may arise from stimula-
tion of lytic phage growth in the presence of beta-lactams 
antibiotics. In fact, bacterial cells divide unsuccessfully 
and create very long filaments in the presence of beta-
lactams, and this cell filamentation contributes to much 
faster phage assembly by simply lysing the cell. Filamen-
tation induces perturbations in the peptidoglycan layer 
which may cause greater sensitivity to the activities of 
phage lysis [30, 31]. In addition, phage attack could alter 
the activity of efflux pump, causing increased sensitiv-
ity to multiple classes of antibiotic agents [32]. So, find-
ings demonstrate the significant enhancement of bacteria 
killing in combination therapy, compared to each treat-
ment alone. Similarly, recent research works have been 
directed at effects of combined use of phages and anti-
biotics on E. coli strain ATCC 13,706, being resistant to 
different antibiotics. Phage ECA2 and antibiotics was 
combined and subsequently, employed to evaluate the 
inactivation of E. coli. In this regard, the combination 
of phage and ciprofloxacin at the sub lethal concentra-
tion remarkably reduced the bacterial level compared to 
using each one alone. Besides, the presence of antibiotic 
at a sub-lethal concentration can control the formation 
of phage-resistant strain. However, at sub lethal doses, 
antibiotics create a phage-antibiotic synergistic effect and 
decrease the bacterial number, but only when bacteria 
are sensitive to the used antibiotics. Of note, ciprofloxa-
cin hinders the enzyme topoisomerase II (DNA gyrase) 
of the bacteria and, subsequently, interferes in nucleic 
acid synthesis, thus affecting phage replication cycle in 
the host bacteria. Therefore, at the Minimum Inhibitory 
Concentration (MIC) dose of this antibiotic, no synergis-
tic effect could occur. Moreover, applying combination 
therapy in conjunction with bacteriostatic antibiotics did 
not lead to a synergistic effect because these antibiotics 
only inhibited bacterial growth and did not reduce the 
number of bacteria besides avoiding the phage replica-
tion. Thus, in total, the efficiency of combination therapy 
of phage and antibiotics is dependent on the antibiotic 
resistance of examined bacteria to used antibiotic and 
antibiotic types (bactericide or bacteriostatic) [29, 33].
As mentioned, phage therapy can be used to inhibit 
MDR UPEC because, besides the appropriate antibacte-
rial effect, it can also destroy bacterial biofilms. However, 
rapid emergence of phage-resistant bacteria has limited 
their use and it is the reason why use of phage cocktails 
and combination treatments should be studied further.
Proteus species
Proteus species play a major role in UTIs and infec-
tions caused by these pathogens divided into two types: 
(a) hematogenous infections, e.g., systemic infections, 
and (b) ascending infections assisted by bacteria to be 
colonized step by step in the urinary tract and to reach 
the kidney eventually [34, 35]. Warren et  al. described 
P. mirabilis, followed by E. coli and K. pneumoniae, as 
the third most common pathogen associated with the 
complicated UTI at a prevalence rate of 12% for infec-
tions [36]. Furthermore, CAUTI occurs in 50% of all 
patients catheterized for 7 days or more, and P. mirabilis 
is the predominant organism in 44% of CAUTIs [37–39]. 
Although treatment with antibiotics is effective in man-
aging most of cases, rise of antibiotic resistance among 
CAUTI-causing bacteria, including P. mirabilis, makes 
the CAUTI treatment harder. This phenomenon high-
lights the importance of novel methods and phage ther-
apy has reemerged to meet medicinal objectives in the 
last decade [40, 41].
In this context, two novel virulent phages including 
vB_PmiP_5460 and 5461 are introduced which belong to 
Podoviridae and Myoviridae families, respectively. These 
phages are used as cocktail-coated catheters to evalu-
ate the possible effect of biofilm reduction, compared 
with the non-phage coated catheters. A reduction in 
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biofilm population in phage-coated catheters is observed. 
Moreover, a clear tendency of phage cocktail leads to 
the remarkable reduction of biofilm formation in 96 and 
168  h after catheterization. These effects are promising 
since urinary catheters remained in the patients’ bladder 
for a long course and the potency of the phage-coated 
catheters lasted for 7 days in this study [42]. Moreover, 
in another investigation, different degrees of sensitivity to 
13 phages in 50 isolates of uropathogenic P. mirabilis in 
planktonic and biofilm forms were reported. Among the 
13 phages, 39APmC32, 65APm2833 (Myoviridae fam-
ily), and 72APm5211 (Siphoviridae family) were selected 
as cocktail components. These phages exhibited a strong 
anti-biofilm activity that had a better potential to inhibit 
biofilm formation rather than to remove mature biofilms 
[43]. It appears that phages can delay the formation of 
biofilms or even hinder their formation by inhibiting the 
growth of P. mirabilis (Fig. 1). Another good anti-biofilm 
feature of phages 39 and 72 A is the production of poly-
saccharide depolymerase, demonstrating the formation 
of halo around plaques. Besides, these phages eradicate 
more than 50% of biofilms in the investigated strains. In 
this way, phage-encoded polysaccharide depolymerase 
degrades bacterial exopolysaccharide which is the main 
component of biofilm matrix. It is remarkable that halos 
are formed by bacteria from which exopolysaccharide 
has been removed through excess phage enzyme released 
during the lysis of infected cells [44, 45]. Furthermore, 
applying the phage cocktails containing several phages is 
a reasonable solution for phages with a narrow host spec-
trum. In a similar fashion, in this study, phage 65 A has a 
low potential for destroying biofilms, but is characterized 
by the widest range of hosts. Authors recommend that 
the addition of the mentioned phage to the phage cock-
tail preparation could lead to increase in the number of 
bacteria susceptible to the cocktail, compared to prepara-
tions containing single phages. Thus, phages 72 and 39 A 
produce polysaccharide depolymerases that promote the 
penetration of phage 65 A into the deeper biofilm layer 
[43].
Similarly, Nzakizwanayo et  al. reported three specific 
P. mirabilis phages which belonged to Podoviridae fam-
ily. All of these phages exhibit polysaccharide depolymer-
ase activity against their host. Furthermore, in the worst 
possible condition where phage is used to treat an estab-
lished infection, use of a single-dose phage cocktail has 
remarkably (3-fold) prolonged the time taken for block-
ing catheters. However, the application of the same phage 
dose in the early phase of infection has led to complete 
inhibition of catheter blockage and eradication of infec-
tion. Additionally, phage treatment of biofilm formation 
caused a significant decrease in the level of encrusta-
tion, compared to control group. The remarkable point 
highlighted by this study is the importance of utilizing 
the phage in the early stage of infection, thus leading to 
full prevention of blockage. In fact, this phenomenon 
may be characterized by the insufficient dose of phage to 
deal with dense bacterial population or the development 
of resistance to the utilized phage [46, 47]. Furthermore, 
another research reported five phages with a remarkable 
ability to disrupt pre-formed MDR P. mirabilis biofilms, 
thus reducing the number of viable cells by 99.9% [48]. 
Moreover, combination therapy of ampicillin and phage 
vB_PmiS-TH against planktonic and biofilm forms of P. 
mirabilis recovered from UTI was used in another work. 
In the planktonic culture, the bacterium was highly sus-
ceptible to combination therapy. Notably, phage-antibi-
otic combination had the highest effect on the removal of 
biofilm after 24 h, which demonstrated the superiority of 
combination therapy to each of therapies alone in terms 
of efficiency. In addition, this treatment could inhibit the 
development of resistance mutant that develops quickly 
in exposure to each one of phage or antibiotics [49].
Up to 30% of all urinary tract stones (struvite) are cre-
ated by P. mirabilis crystalline-shaped biofilms in the 
urinary tracts. The flow through catheters is recurrently 
blocked by these crystalline structures and then, bac-
teria embedded in crystalline biofilms become highly 
resistant to immune system as well as routinely used 
antibiotics [50, 51]. In this regard, finding a treatment to 
inhibit the biofilm of this bacterium can prevent CAUTI. 
As reported in the mentioned studies, phages can have 
excellent inhibitory performance against P. mirabilis bio-
film, although further studies are required to determine 
how they can be used to maximize efficacy. In addition, 
the use of phage cocktails can target a wider range of 
microorganisms, and the use of a combination of phages 
with antibiotics increases the chances of eradicating the 
infection. Therefore, the use of phages to control CAUTI 
caused by Proteus species should draw much more 
attention.
Klebsiella pneumoniae
Klebsiella pneumoniae are reported as one of the main 
opportunistic pathogens with the ability to cause hos-
pital-acquired UTIs predominantly in the elderly, new-
borns, and immunocompromised individuals [52]. 
Dissemination of antibiotic resistance, especially to car-
bapenem, fluoroquinolones, and colistin, is becoming 
increasingly serious and only a few remaining therapeu-
tic options remain to treat Pan-Drug-Resistant (PDR) K. 
pneumoniae infections. In this respect, the spread of PDR 
K. pneumoniae species worldwide threatens modern 
medicine to revert to its pre-antibiotic era [53, 54]. Thus, 
one of the possible options to inhibit these pathogens is 
to use phages due to their well-defined target spectrums 
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and host range specificity [55]. In this section, we will 
discuss the specific function of phage therapy to inhibit 
K. pneumoniae in UTIs.
Sybesma et  al. isolated nine K. pneumoniae strains 
(includes ESBL-producing strains) from urinary cul-
ture of different patients with UTIs and investigated the 
in vitro susceptibility to phages. Notably, all of these lytic 
phages were prepared from the phage collection of the 
George Eliava Institute of phage and were used in the 
bacterial cell lysis screening assay. The authors reported 
that v_BR–KpS10 could lyse all K. pneumoniae strains. 
Hence, this study proposed that existing commercial 
phages could be used more to control MDR K. pneumo-
niae UTI. Furthermore, the data in this study indicated 
that phage and antibiotic susceptibility/resistance were 
not related to each other and although there was resist-
ance to various antibiotics in the K. pneumoniae strains, 
they were all lysed by one of the phages [56]. In another 
study, one lytic phage, KPO1K2, was isolated from efflu-
ent water to inhibit K. pneumoniae. This phage was a 
member of Podoviridae family with T7-like specifications 
and was proved stable over a wide pH range of 4–11. 
According to the spot test, phage was found to infect 
28% (7/28) of K. pneumoniae. Furthermore, phage kinet-
ics for its in vivo stability was conducted in mice. After 
intraperitoneal injection into mice, KPO1K2 titers in 
urinary bladder and kidney clearly indicated that phage 
accumulation occurred at higher concentrations in these 
two organs. Notably, in addition to K. pneumoniae, 
KPO1K2 infected E. coli. Since these bacteria are known 
for causing UTI, interestingly, both of them are sensi-
tive to a single phage [57]. In a similar study by Zhang 
et  al., novel phage vB_KpnP_IME279 was isolated from 
hospital sewage for lysis of MDR K. pneumoniae iso-
lated from urine. This phage belongs to Podoviridae and 
is stable in a wide pH range between 3 and 11 and tem-
perature range between 40 and 60 °C. It should be noted 
that vB_KpnP_IME279 has lytic functions against sev-
eral tested K. pneumoniae. Furthermore, phage genome 
analysis reveals that the investigated phage does not con-
tain a toxin gene, which provides safety guarantee for the 
future clinical treatment of this phage [58]. Therefore, 
the reported phages did not lose their activity even at 
extremes of pH; thus, it appears that they enjoy higher 
and longer stability in urinary bladder and kidney. In this 
context, these studies recommended phage therapy as a 
suitable candidate and a biocontrol strategy to treat MDR 
K. pneumoniae-associated UTI; however, control trails in 
this field are essential.
Recent researches reported K. pneumoniae capsule 
and biofilm as the most important virulence factors 
that have multiple functions such as adhesion to differ-
ent surfaces and protection of the bacterium from lethal 
serum components, immune clearance, and environ-
mental factors [53, 59]. Therefore, isolation and iden-
tification of phages that can inhibit and destroy these 
bacterial virulence factors is necessary to control UTI. 
In a recent publication, Phage 117 and Phage 31 were 
isolated and characterized. Then, the host range and 
lytic potential of these phages were tested by spotting 
nine carbapenamase-producing and hypermucoviscous 
K. pneumoniae (ST11 and blaKPC-2 gene positive) iso-
lates from elderly patients with UTI. The use of each 
phage alone provided the potential to lyse K. pneumoniae 
strains. Subsequent culture and urine experiments with 
Phage 117 showed a strong lytic activity of the phages 
at first. Nevertheless, observation of rapid regrowth fol-
lowing the initial lysis suggested that phage-resistant 
mutants were selected among the host populations. On 
the other hand, the phage cocktail (117 + 31) had remark-
ably higher antimicrobial activity than Phage 117 alone. 
In this respect, the authors suggested that phage cocktail 
could act as a promising choice for phage therapy to con-
trol K. pneumoniae due to its potential ability to infect 
phage-resistant mutants and thus, delay the develop-
ment of bacterial resistance. Although phage predation 
affected the assembly or synthesis of capsule expression, 
it had no significant effect on the biofilm formation [60]. 
Also, another study reported a phage, vB_KpnS_Kp13, 
that was effective against all Verona integron-encoded 
metallo-β-lactamase producing K. pneumoniae (ST15 
and expressing the K24 capsule) originating from differ-
ent hospital samples such as urine. Although this phage 
showed a narrow host range, no phage-resistant strains 
were identified in this study; thus, this phenomenon 
strongly suggested that the target of this phage could be 
related to strain survival. Of note, vB_KpnS_Kp13 had 
a quite efficient function in killing encapsulated bacte-
ria; the results of analyzing its genome showed that the 
specific feature of the capsule depolymerase, encoded by 
ORF2, of this phage provided the mentioned function. 
Furthermore, the phage significantly degraded biofilm 
and reduced the biomass by ~ 73% in 48 h post-treatment 
[55].
In this respect, in another study, a phage 0507-KN2-1 
was isolated for a new capsular type of K. pneumoniae 
(KN2) UTI isolates. This phage was categorized as a 
member of the Myoviridae phage family and the analy-
sis of the genome indicated a putative polysaccharide 
depolymerase encoded by 3738-bp gene. A recombinant 
form of this protein was produced and was analyzed for 
confirmation of its enzymatic activity and specificity to 
capsular polysaccharides. Then, in spot tests, this puri-
fied depolymerase led to decapsulation of K. pneumoniae 
strains. Notably, this protein was specific to KN2 capsular 
polysaccharides and was not able to induce digestion-like 
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spots on K. pneumoniae strains with another type of cap-
sule or KN2 capsular polysaccharide mutant [61]. Fur-
thermore, in another work, Siphoviridae phage TSK1 
showed a potent lytic activity against K. pneumoniae. This 
phage had a narrow host range and enjoyed the highest 
stability at pH 7 at a temperature of 37 °C. Besides, post-
treatment with TSK1 caused a reduction in K. pneumo-
niae biofilms biomass (of different ages). Pre-treatment 
of K. pneumoniae biofilm with TSK1 decreased bio-
mass > 99 % in the first 24 h of incubation. Therefore, this 
study recommended that due to TSK1 stability at alkaline 
pH, this phage can be employed as a medicinal agent for 
K. pneumoniae-mediated UTIs, while it is not suitable for 
direct oral administration. Also, due to the higher abil-
ity of TSK1 to destroy bacterial biofilm, this phage can be 
utilized in the impregnation of urinary catheter to hinder 
CAUTIs [53].
It seems that phages and recombinant depolymerase 
can be used as therapeutic strategies to control K. pneu-
moniae UTI, given that phages can prevent or destroy the 
most important virulence factors of this bacteria such as 
capsules and biofilms through capsule-polysaccharide 
specific depolymerase. Of note, this enzyme is required 
for degradation of capsule and adsorption onto the host 
cell. Consequently, following the degradation of capsule, 
the exposure of outer membrane components to phage 
for better accessibility occurred. On the other hand, 
according to findings, phage depolymerase acts specifi-
cally against a specific capsule type and isolated phages 
usually have a narrow host range and can only be used 
for a specific bacterial strain. Therefore, phage can be 
employed in combination with other phages in phage 
cocktails and with antibiotics to combat K. pneumoniae 
in UTIs.
In general, in addition to UPEC, Proteus species, and 
K. pneumoniae that have been studied further in the field 
of phage therapy to control UTIs, other researchers have 
investigated the effect of phages on uropathogenic bacte-
ria. In this manner, Table 1 lists the recent related stud-
ies that used phages to inhibit different uropathogenic 
bacteria.
Multi‐species cocktails
The prevalence of antimicrobial resistance causes obsta-
cles to a successful treatment and also, biofilm-based 
infections create even more challenges these days; there-
fore, phage therapy could be a useful choice in combating 
MDR uropathogenic bacteria such as Proteus spp. and 
E. coli. In this manner, a study investigates the activities 
of three commercial phage cocktails (Septaphage, PYO 
and INTESTI) against 70 MDR E. coli and 31 Proteus 
spp. (including 15 MDR strains) collected from human 
Table 1 Recent studies used phage therapy to inhibit the most common uropathogenic bacteria
MDR: Multi-drug resistant; VRE: vancomycin-resistant enterococci
Uropathogenic bacteria Properties Phage Outcome Reference
Enterobacter cloacae MDR E-2, E-3 and E-4 were isolated from waste 
water
The growth of the bacteria was inhib-
ited by the three phages. Notably, 
the use of cocktails with two or three 
phages was significantly more effec-
tive than each one alone. In urine, the 
inactivation was still effective
[65]
Enterococcus faecalis Clinical isolates vB_EfaS_GEC-EfS_3 (Siphoviridae) isolated 
from sewage
While phage was able to infect a broad 
range of strains of the same species 
as the host species from which they 
were isolated, they were unable to 
infect other host species tested
[66]
Enterococcus faecalis VRE vB_EfaS_HEf13 (genus Sap6virus in the 
family Siphoviridae) was collected from 
a local sewerage system
The lytic activity of phage HEf13 at 
various multiplicities of infection 
consistently inhibited the growth of 
diverse clinical isolates of E. faecalis 
without any lysogenic process
[67]
Streptococcus mitis Clinical isolates vB_SmM_GEC-SmitisM_2 (Myoviridae) 
isolated from sewage
This phage was able to productively 
infect 9 of 16 S. mitis strains, but none 
of the other species in our collection
[66]
Staphylococcus saprophyticus MDR Clinical isolates vB_SsapS-104 (Siphoviridae) was isolated 
from hospital wastewater
This phage represented high anti-
bacterial activities against S. sapro-
phyticus isolates in vitro, as it was 
able to lyse 8 of the 9 clinical isolates 
(88.8%). Notably, no lytic activity was 
observed on some other pathogenic 
bacteria tested
[68]
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and non-human origins. These cocktails were produced 
by Georgian institutions including PYO and INTESTI 
from Eliava BioPreparations and Septaphage from Bio-
chimpharm. The percentages of the susceptibility of 
E. coli strains to PYO, INTESTI, and Septaphage were 
61.4%, 67.1%, and 8.6%, respectively. Also, the suscepti-
bility of Proteus spp. to PYO, INTESTI, and Septaphage 
was 29.0%, 38.7%, and 19.3%, respectively [62]. Interest-
ingly, Septaphage almost represented no activity against 
the investigated strains. This difference among bioprepa-
rations results from different production methods and 
contents that caused insufficient phage titer of the final 
product [63]. Therefore, it appears that the function of 
commercial phage cocktails to inhibit MDR bacteria is 
more limited. This narrow activity could result from the 
absence of specific phages targeting contemporary MDR 
strains which are spreading in different settings. There-
fore, the specific phages for the emerging MDR bac-
teria should be isolated, well characterized, and then, 
integrated into conventional biopreparations [62, 64]. 
Because it is only in this case that commercial phage 
cocktail can be used to treat MDR UTI around the world.
Phages inhibition for other uropathogenic 
bacterial biofilm
As discussed in the previous sections, phages have the 
ability to destroy the biofilm of bacteria that cause UTI; 
however, during the course of this infection, different 
bacteria forms mixed-species biofilm on in-dwelling 
medical devices or host organs. So, using a specific phage 
of bacterial species cannot completely eradicate the 
infection [69].
In a recently published paper, a cocktail consisting of 
MDR A. baumannii infecting phages (Aba 1–6) with 
highly lytic activities varying from 56 to 84% was used 
to destroy the bacterial biofilm in combination with 
antibiotics in human urine. The usage of all phages sig-
nificantly reduced A. baumannii biofilm biomass, and 
Aba-1 appeared to be having the highest antibiofilm 
activity in the urine condition. Furthermore, the use 
of phage cocktail in combination with trimethoprim/
sulfamethoxazole (SXT) and ciprofloxacin led to bio-
film biomass reduction rates of 94.3 and 93.3%, respec-
tively. Furthermore, in most cases synergistic effect also 
causes the limitation of persister cell regrowth. Of note, 
combination therapy with gentamicin, tobramycin, imi-
penem, and meropenem similarly induced a more sig-
nificant reduction in A. baumannii biofilm biomass than 
the phage cocktail-treated control. On the other hand, 
combination therapy with colistin did not present the 
same expected outcome as its mentioned counterparts 
mentioned above. The synergistic impact can be clari-
fied by the antibiotics mode of activity. Antibiotic-related 
changes within the bacterial cell morphology empow-
ered fast phage development and cell lysis. Besides, the 
set of phage lytic enzymes, particularly those responsible 
for local peptidoglycan degradation, could enhance anti-
biotic penetration through biofilm matrix. On the other 
hand, combination of phage and colistin did not have 
synergistic effect because colistin destabilized the bacte-
rial cell membrane and could limit phage propagation. 
In addition, overexpression of the efflux pump and auto-
inducer synthase AbaI that accelerate the synthesis and 
transport of acylated homoserine lactones can be related 
to the increase of biofilm formation. Therefore, combined 
treatment can destroy the biofilm of MDR A. baumannii 
in UTI through such mechanisms as enzyme-mediated 
permeabilization of membranes, digestion of the biofilm 
matrix, and enhancement of antibiotics activity. In addi-
tion, phage therapy can target persister cells through 
antibiotic treatment. Nevertheless, this activity may 
depend on the type of bacterial pathogen and the antibi-
otic used [10, 70].
 In another investigation by Yang et al., PHB08, a viru-
lent E. faecalis phage, and its endolysin (lys08) demon-
strated antibiofilm activity against E. faecalis biofilms 
isolated from UTI. Different analyses revealed that the 
mentioned phage belonged to Siphoviridae family and 
exhibited great stability at different temperatures (4–60 
°C) and pHs (between 5.0 and 9.0). Furthermore, this 
phage infected 79% (15/19) of the E. faecalis clinical iso-
lates tested, but had no effect on other bacterial species 
such as E. faecium. Both phage and its endolysin remark-
ably decreased bacterial biofilm density. So, this study 
also suggested phage and endolysin as possible biocon-
trol agents that could destroy the biofilm formation of E. 
faecalis. Additionally, high stability of phages in different 
environmental conditions can increase their use in UTI 
[71]. Another interesting study on two-species biofilms 
investigated the effectiveness of hydrogel silicone uri-
nary catheter treated with phage cocktail in inhibition 
of biofilm formation by a mixture of P. mirabilis and P. 
aeruginosa in an in vitro model using artificial urine. The 
observations indicated that pre-treatment with phage led 
to reduction of P. mirabilis biofilm number by > 2  log10 
CFU/cm2, while this value was 4  log10 CFU/cm2 for P. 
aeruginosa over 48 h. Notably, the presence of P. mirabi-
lis always causes an increase in lumen pH from 7.5 to 9.5 
and such a high pH has no inhibitory effect on the func-
tion of phages in the catheter model. On the other hand, 
survival of bacterial population was reported for both 
pathogens in the anti-biofilm assay. However, plaque for-
mation observed on the plates with the recovered adher-
ent bacteria implied that large fractions of these bacteria 
were not truly phage resistant [72]. This phenomenon 
may be related to metabolic alternation of bacteria in 
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biofilm community, especially cells in the dipper layer of 
biofilm that did not support phage replication following 
infection. Another alternative explanation could be “spa-
tial refuges” in which resistant bacteria create a physical 
barrier for susceptible cells against phage invasion [44, 
72]. Therefore, the authors proposed that it was pos-
sible to use phages in indwelling urinary catheters with 
high pH conditions. Additionally, phages can be used to 
inhibit multiple species in mixed-species biofilms with-
out interfering in the lytic capacities of the other phages. 
These findings demonstrate the possibility of applying a 
phage cocktail to CAUTIs because the introduction of a 
foreign body in the urinary tract facilitates higher micro-
bial colonization and mixed-species biofilm formation.
In another research, it was also reported that pre-treat-
ing urinary catheter with P. aeruginosa specific phage 
ΦE2005-A and E. coli HU2117 had a synergistic protec-
tion against the formation of P. aeruginosa biofilm on 
catheters. In this regard, silicone catheter segments were 
exposed to phage plus E. coli and challenged by P. aerugi-
nosa; then, incubation occurred in the human urine sam-
ple up to 72 h. The result showed that this pre-treatment 
led to the lower adherence of 4  log10 unit of P. aeruginosa 
to the catheter than no pre-treatment. It is worth men-
tioning that due to the specificity of the phage host, the 
presence of special Pseudomonas phage did not consider-
ably interfere in E. coli HU2117 communities [21]. These 
discoveries revealed that the combination of phage and 
probiotic bacterium interference would lead to the atten-
uation of biofilm formation by P. aeruginosa on urinary 
catheters. This phenomenon results from the fact that 
the use of specific P. aeruginosa phage reduces the initial 
population of this bacterium, a process that allows the E. 
coli biofilm to be established easier. Therefore, mixed bio-
film does not form because the combined effect of micro-
bial competition and lytic phage infection may lead to the 
predominance of one species in the biofilm. However, the 
use of phages and E. coli alone did not show good out-
comes Because it seems that E. coli was unable to out-
perform P. aeruginosa and using the phage solitarily was 
obviously insufficient to destroy all P. aeruginosa cells 
prior to mixed biofilm formation on the catheter [21, 73].
The definite role of catheter-associated biofilms in 
UTI is poorly known; however, there is evidence that 
this kind of biofilms has a major role as the stable reser-
voir of uropathogenic microorganisms, which are resist-
ant to antimicrobial and it is difficult to eliminate them 
even with the catheter removal. Therefore, prevention 
and removal of bacterial biofilm is very important in the 
treatment of UTIs. In this context, phages have been 
reported as one of the most significant candidates for 
inhibiting bacterial biofilm. However, bacterial biofilms 
are usually produced by several different pathogens and 
cannot be completely eradicated using a specific phage 
(Fig. 1) [74]. Therefore, as mentioned in the above stud-
ies, the combined use of several different phages as phage 
cocktail, the combined treatment of phages and antibiot-
ics, and the use of probiotics along with phages can help 
inhibit the mixed biofilm further. Furthermore, it may be 
useful to investigate the possible synergistic interactions 
between phage cocktails and other antimicrobial strate-
gies such as biofilm inhibitors, catheters with more rou-
tine antibacterial substances or bacterial interference. 
Notably, despite the use of different combination thera-
pies, phage-resistant bacteria are still reported in stud-
ies; however, with the use of combination therapies, their 
population is greatly reduced. Therefore, it is very impor-
tant to identify more effective strategies to kill all bacteria 
in the biofilm and prevent the development of resistance 
to phages. In doing so, the true value of these treatments 
is determined when used in in vivo and clinical studies.
In vivo and clinical use of bacteriophage 
for the treatment of UTIs
As fully discussed in the previous sections, the use of 
phages to inhibit bacteria that cause UTIs has been 
reported in many in  vitro studies. On the other hand, 
phage therapy has not been well received in clinical and 
in  vivo researches. Nonetheless, we will discuss clinical 
and in vivo studies that have used phages to control and 
treat UTIs.
In the case of a 60-year-old male patient who under-
went kidney transplantation, multiple chronic UTIs with 
an MDR K. pneumoniae were reported. During each 
hospital stay, the patient was treated for 12–14 days 
with meropenem alone or meropenem with colistin and 
it yielded rapid, yet temporary, resolution of infection 
symptoms. After 10 severe cases of UTI with hospitali-
zations, phage therapy was used to treat the infection. 
In this regard, the intra-rectal application (10 ml twice 
daily) of the specific phage preparation against the MDR 
K. pneumoniae strain was used; however, after five days, 
the patient’s condition worsened and ultrasound exami-
nation showed polycystic kidneys. Therefore, a combina-
tion of meropenem and phage was used and after 18 days 
of this treatment, progressive remission of clinical signs 
was observed. Due to multiple recurrent infections and 
unsuccessful outcomes, the patient was selected eventu-
ally for a planned resection of his left polycystic kidney 
[75]. In this patient, the main source of infection was 
cysts in the left kidney that caused several therapeutic 
failures; surgical intervention achieved the best therapeu-
tic outcomes. Furthermore, due to the combined use of 
phage and antibiotics for the treatment of the patient, it 
is difficult to evaluate the exact function of phage ther-
apy, but it seems that the infection in the transplanted 
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kidney could be controlled through phages. On the other 
hand, shortly after the use of phage therapy, it is possible 
that phage may have facilitated the selection of phage-
resistant bacteria. Thus, the use of phage cocktails or 
combination therapies with antibiotics can be helpful 
[76]. Notably, K. pneumoniae isolated from the patient 
were completely sensitive to the colistin; however, after 
12 days, antibiotic therapy stopped on the suspicion of 
nephrotoxicity. However, long-term (29 days) use of 
phages and phage lysate application were safe, particu-
larly in relevance to the long-term kidney function and 
allograft tolerance.
Phage therapy was also used in another 63-year-old 
female patient with recurrent UTI caused by Extensively 
Drug-Resistant (XDR) K. pneumoniae. It is noteworthy 
that, this bacterium was completely resistant to all tasted 
antibiotics except polymixin B and tigecycline. This 
patient was treated by antibiotics, but due to antibiot-
ics utilization, complication became increasingly severe. 
Hence, she agreed to a phage therapy clinical trial and 
then, phage cocktail consisted of five lytic phages, used 
for the first round by bladder irrigation. This phage ther-
apy regimen (Cocktail I) failed to completely kill the bac-
teria, and phage-resistant bacteria were isolated. In this 
respect, another cocktail (Cocktail II) was used, which 
included specific phages against bacteria isolated from 
the patient. Unfortunately, phage-resistant bacteria were 
isolated again. Thus, it was hypothesized that the com-
bined use of phages and non-active antibiotics against 
bacteria could be helpful and in this way, the combined 
use of bladder-irrigated cocktails (Cocktail III) and oral 
SXT showed strong synergistic effect and the recurrent 
UTI symptoms subsequently disappeared [20]. Therefore, 
the findings of this study suggested combining the phage 
cocktail with antibiotic in the treatment of recurrent UTI 
in order to lower the risk of regrowth of phage-resistant 
mutants. It seems that the rapid onset of phage-resist-
ant strains has been due to the poor functioning of the 
patient’s immune system, given that a proper immune 
system function is essential to the clearance of bacte-
rial infection [77]. However, more molecular studies are 
Fig. 1 Catheter-associated urinary tract infections (UTI) and different aspects of bacteriophages therapy for inhibition and destruction of 
multiple-species biofilm. a The use of bacteriophages in combination therapies can increase the penetration of antibiotics into the deeper layers of 
the biofilm. b bacteriophages can control UTI by killing bacteria and inhibiting their virulence factors such as capsules. c The use of bacteriophage 
cocktails can be an effective to inhibit multiple-species biofilm in the UTI
Page 10 of 13Chegini et al. Ann Clin Microbiol Antimicrob           (2021) 20:30 
required to understand the exact mechanism of resist-
ance to phage cocktails.
A recently published study by Ujmajuridze et al. evalu-
ated different characteristics of phage therapy such as 
feasibility, tolerability, safety, and clinical/microbiological 
outcomes in patients with UTIs. In this way, PYO phage 
(phage cocktail consisting of phage lines is activated 
against a broad spectrum of uropathogenic bacteria) pro-
duced by Eliava was used. After in vitro phage sensitivity 
test, the hospital was informed of PYO phage solution to 
initiate the clinical analysis. After Transurethral Resec-
tion of Prostate (TURP), suprapubic and transurethral 
catheters were inserted to maintain phage cocktail irriga-
tion. Then, after one to two days, the transurethral cathe-
ter was removed, while the suprapubic catheter was kept 
in place for another 7 days to facilitate the adapted phage 
cocktail instillation. Total sensitivity of 41% was reported 
in in  vitro analysis. Besides, in in  vivo pilot series, 67% 
(6/9) of patients’ bacterial titers were reduced after phage 
treatment. Notably, no phage-associated side effect was 
reported. So, the authors suggested that phage therapy 
could be safe and effective in UTI treatments [78].
 In a study conducted by Nishikawa et al., UPECs were 
injected transurethrally into the mouse bladder. Then, 
purified phages T4 and KEP10 (Myoviridae family) were 
immediately injected into the peritoneal cavity of mice 
to treat UTI. The findings manifested that phages could 
save a large percentage of mice (up to 90%) from death 
through a dose-dependent infection. On the other hand, 
all mice in the control group that were not treated after 
infection died within 3 days. Notably, no specific side 
effects were reported for any of the phages. Moreover, 
the results illustrated that these phages moved rapidly 
into the bloodstream and disseminated into internal 
organs and they remained stable for 24 h at most in the 
human and mouse urine samples at 37 °C. Therefore, the 
authors reported T4 and KEP10 as suitable therapeutic 
phages for treating lethal UTI [79]. Finally, in another 
in vivo study on mice, UTI was induced by transurethral 
application of Cronobacter turicensis. At the same time, 
specific phages against this bacterium were administered 
intraperitoneally. The authors reported that phage ther-
apy decreased the number of bacteria in the kidney by 
70%. Phage therapy reduced the higher levels of malon-
dialdehyde by 39% without any effect on the antioxidant 
status. Notably, there was no significant difference in 
Cronobacter colonization of the bladder between infected 
and phage treated groups. Furthermore, the expression 
of pro-inflammatory cytokines such as monocyte che-
moattractant protein-1 and tumor necrosis factor-alpha 
increased due to the infection, while it was attenuated 
by phage therapy. The authors report that differences 
in the function of phages in the kidney and bladder can 
be related to the kinetics of phages after intraperitoneal 
administration, which could be improved by choosing 
another application route [80].
Therefore, the finding of various studies represented 
that phage therapy could be used to control UTI caused 
by MDR bacteria, although there are still many limita-
tions in this treatment regimen. The administration of 
phages varied in different studies and there is still no 
comprehensive guideline on how to use them to ensure 
the highest clinical performance. Therefore, more clini-
cal trials are needed to fully evaluate the safety and effi-
ciency of potential therapeutic applications in  vivo. 
Further, when a specific phage is used alone, the risk of 
development of phage-resistant mutant is very high. In 
this regard, the use of phage cocktails can be an effective 
solution because different phages use different receptors 
to minimize the development of resistance and widen 
the host range, which is important in the case of nar-
row host range infecting phages. However, as reported 
in the mentioned studies, resistance to cocktails has also 
occurred, but their molecular mechanisms have not yet 
been elucidated. Thus, the combined use of phage cock-
tails and different antibiotics increases the chances for 
controlling the UTI. At last, those antibiotics that are 
effective against uropathogenic bacteria such as poly-
mixin and tigecycline are not usually used for a long time 
due to their many side effects, especially nephrotoxicity, 
although various studies have not reported the specific 
side effects of phages, which could lead to their wide-
spread use in treatment of UTIs.
Conclusion
MDR Uropathogenic bacteria have reduced the utility of 
chemical antibiotics in clinical settings. Moreover, these 
antibiotics are cytotoxic to not only pathogens, but also 
health-beneficial commensals. In this regard, phages and 
their derivatives were reported as an alternative strategy 
for the treatment of drug-resistant UTI. Recent studies 
found that phages, in addition to inhibiting uropatho-
genic bacteria, could destroy their biofilm. Besides, the 
safety profile of these microorganism seems to be far 
better than antibiotics. Therefore, researchers suggested 
phage therapy as a mean for prevention and treatment of 
UTI and further spread of MDR uropathogenic bacteria. 
However, phage-resistant strains still occur despite the 
use of phage cocktails and combination therapy. In this 
context, more fundamental studies are required to deter-
mine the phage–host interactions and the phage poten-
tial to control UTI. Additionally, most of phage therapy 
data were obtained from in  vitro studies and the major 
limitation was lack of appropriate clinical research. So, 
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further clinical trials (double-blind and placebo-control) 
are needed to investigate dose, best routes of administra-
tion, frequency and duration of phage therapy for inhibi-
tion and treatment of UTI.
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